Refine your search

Search Results within category "Arthritis & Rheumatic Diseases"

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

Search all categories

Suggestions within category "Arthritis & Rheumatic Diseases"


7 Study Matches

Physical Therapists Role in Promoting Physical Activity for People with Chronic Physical Disabilities

We plan to conduct a qualitative study exploring perspectives of physical therapists and people with disability regarding physical activity promotion
Jacob Corey at jjc6062@psu.edu or 814-865-1691
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
At least 18 years of age
Fluent in english
Individual with a physical disability (eg. limb amputation, spinal cord injury, spinabifida, cerebralpalsy, arthritis, motor impairment)
Has participated in physical therapy in the last year
Exclusion Criteria:
Under the age of 18
Does not speak fluent english
does not have a physical disability
Has not participated in physical activity in the last year
Arthritis & Rheumatic Diseases, Neurology, Muscle & Bone
  Email this study information to me
  Contact the study team

Couples' Daily Lives with Chronic Back Pain

The purpose of this study is to learn more about the daily experiences of people with back pain and their spouse/partner. Participants and their spouse/partner will be interviewed by video using a tablet computer every 6 months for 2 years and will be asked to complete daily surveys twice a day for 30 days using the provided tablet computer. The daily surveys will take about 5 to 10 minutes to complete. Questions for the interviews and daily surveys focus on physical symptoms, feelings, activities, and interactions.
Kari Whitehead at couplesstudy@psu.edu or 814-865-7094
All
18 year(s) or older
This study is also accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Individuals with back pain at least 65 years or older
Experienced moderate or severe back pain for at least 3 months
Married or in a long-term relationship AND living with spouse or partner
Exclusion Criteria:
Does not work more than 20 hours a week outside the home
Arthritis & Rheumatic Diseases, Pain Management
  Email this study information to me
  Contact the study team

Investigation of Remission in Rheumatoid Arthritis

This is an experimental observation study of Rheumatoid arthritis that will examine remission in rheumatoid arthritis by (1) collecting biospecimens of rheumatoid arthritis subsets with collection of clinical data and (2) investigation of etiology of immune tolerance in rheumatoid arthritis.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of Rheumatoid Arthritis by a Rheumatologist
Patient of Penn State Hershey Rheumatology
Exclusion Criteria:
No other connective tissue autoimmune disease other than Sjogren's Syndrome
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Study of Antimalarials in Incomplete Lupus Erythematosus (SMILE)

This is a study to test whether a widely-used drug, hydroxychloroquine, might slow the progression of lupus like features in individuals who are at high risk for developing systemic lupus erythematosus. This will be measured by the accumulation of clinical and laboratory features of lupus. The study will randomize subjects to the active drug, hydroxychloroquine, or placebo, with an equal chance of receiving either treatment. The study treatment lasts approximately 2 years with visits approximately every 3 months.
Jamie Carter at jcarter3@pennstatehealth.psu.edu or 717-531-4921
All
All
This study is NOT accepting healthy volunteers
NCT03030118
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Positive for ANA (antinuclear antibodies)
Age 18 to 49 years, inclusive
Have never taken hydroxychloroquine
Exclusion Criteria:
Previous use of immunosuppressive drugs
Diagnosis of systemic lupus erythematosus
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus

This study is for patients with Systemic Lupus Erythematosus (SLE) to test the effect, safety, and tolerability of the experimental drug JBT-101 in people with SLE to see if JBT-101 stops inflammation and how well JBT-101 is tolerated. The study will evaluate whether JBT-101 will decrease the pain associated with active arthritis or tendonitis in SLE patients.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT03093402
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Be willing to not start or stop any NSAID or disease modifying treatments for SLE during the study
Be wiling to not use any legal or illegal cannabinoids, including FDA-approved cannabinoids during study participation
If female of child-bearing potential must be willing to use highly effective contraception during study participation
Exclusion Criteria:
Treatment with steroids in the past 28 days
Actively listed on organ transplant list or have received an organ transplant other than a corneal transplant
Have active or chronic infections
Have a history of cancer (except cervical treated successfully with curative therapy or basal cell carcinoma)
Have a history of significant heart disease
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy

This study is for patients with active Systemic Lupus Erythematosus(SLE) to test the effect and safety of different doses of the experimental drug AMG 570. To see if AMG 570 is a treatment option for SLE patients who are not responding to current standard of care.
All
18 year(s) or older
This study is NOT accepting healthy volunteers
NCT04058028
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Diagnosis of SLE
Exclusion Criteria:
Active infection
Pregnant or breastfeeding
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA

Observational Study for Pediatric Rheumatic Diseases: The CARRA Registry

The original Childhood Arthritis & Rheumatology Research Alliance (CARRA) Registry was first established in 2010 to advance alliance infrastructure,facilitate expanded clinical and translational pediatric research, and transform the culture of pediatric rheumatology toward universal participation in research. Continuation of the CARRA Registry as described in the protocol attached to this IRB submission will support data collection on patients with pediatric-onset rheumatic diseases. The CARRA Registry will form the basis for future CARRA studies. In particular, this observational registry will be used to answer pressing questions about therapeutics used to treat pediatric rheumatic diseases, including examining safety questions. The Duke Clinical Research Institute (DCRI) is serving as the CARRA Clinicaland Data Coordinating Center (CDCC) for this protocol.
Meredith Buckley at mbuckley@pennstatehealth.psu.edu
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
N/A
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
Onset of rheumatic disease prior to age 16 years for Juvenile Idiopathic Arthritis
Onset prior to age 19 years for all other rheumatic diseases
Willing to participate in a registry you will be followed during your treatment and have information about you disease and treatment collected.
Exclusion Criteria:
More than 21 years of age.
Arthritis & Rheumatic Diseases
  Email this study information to me
  Contact the study team
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA